Summary & Overview
CPT 1000T: Urethral Sphincter Muscle Progenitor Cell Injection
Headline: New CPT code 1000T defines autologous muscle progenitor cell injection into the urethral sphincter.
Lead: CPT code 1000T captures a targeted procedure in which a provider injects a patient’s own muscle progenitor cells into the urethral sphincter, with cystoscopy and ultrasound imaging performed as needed. The code represents a tissue-based therapeutic approach aimed at improving sphincter muscle function for patients with certain types of urinary incontinence.
What this code represents and why it matters: As a distinct procedural code, CPT code 1000T standardizes reporting for autologous muscle progenitor cell injections into the urethral sphincter, enabling clearer tracking of utilization, outcomes, and coverage decisions nationwide. The code matters for clinicians, billing teams, and payers because it delineates a specialized regenerative technique that may affect reimbursement pathways and prior authorization processes.
Key payers covered: Analysis typically addresses major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
What readers will learn: The publication provides benchmarks for utilization and reimbursement where available, summarizes clinical context for the procedure, outlines common coding and billing considerations tied to the service line, and notes relevant policy developments affecting coverage and prior authorization. Data not available in the input will be noted explicitly in specific sections.
Billing Code Overview
CPT code 1000T describes a procedure in which the provider injects the patient’s own muscle progenitor cells into the urethral sphincter to improve sphincter muscle function. The procedure may include cystoscopy and ultrasound imaging when performed.
-
Service type: Autologous muscle progenitor cell injection for urethral sphincter augmentation
-
Typical site of service: Ambulatory surgical center or hospital outpatient setting where cystoscopy and ultrasound-guided injections are performed
Clinical & Coding Specifications
Clinical Context
A 58-year-old female with a history of stress urinary incontinence refractory to conservative therapy (pelvic floor physical therapy, pessary) presents for autologous muscle progenitor cell injection into the external urethral sphincter to improve urethral sphincter function. Pre-procedure evaluation includes a focused history, physical exam, urinalysis to exclude infection, and urodynamic testing or cystoscopy results documenting sphincteric deficiency. On the day of service, the patient is placed in lithotomy position; the provider harvests a small skeletal muscle biopsy (often from the thigh), processes the tissue to isolate and expand muscle progenitor cells per protocol, and injects the patient’s own cells into the external urethral sphincter under direct visualization using cystoscopy and/or transperineal ultrasound guidance. Local anesthesia with or without sedation is used; monitoring and standard sterile technique are maintained. Post-procedure instructions address activity restrictions, voiding diary, and follow-up to assess continence and potential need for repeat treatment. Typical site of service is an outpatient ambulatory surgery center or hospital outpatient department; this is a procedure performed by specialists in urology, Female Pelvic Medicine and Reconstructive Surgery, or reconstructive pelvic medicine programs.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | When a distinct E/M visit is performed on the same day as the procedure for an unrelated or separately identifiable issue |